> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Viking Raised $575 Million In Stock And Debt In September, Yet Holds A $500 Million Buyback Unused
- URL: https://www.bullished.co/viking-raised-575-million-in-stock-and-debt-in-september-yet-holds-a-500-million-buyback-4153d0d1/
- Published: 2026-10-29T11:14:00.000Z
- Updated: 2026-10-29T11:14:00.000Z
- Description: The obesity-drug developer's 10-Q shows $960.0 million in cash, a $500.0 million repurchase plan and third-quarter R&D of $166.8 million.
- Author: Matteo Parrino
- Tags: Earnings, VKTX, Industry: Healthcare

[Viking Therapeutics](https://www.bullished.co/tag/vktx/), a clinical-stage drug developer focused on obesity and other metabolic disorders, sold [9,035,714 shares at $35.00 each](https://www.sec.gov/Archives/edgar/data/0001607678/000119312526436432/vktx-20260930.htm?ref=bullished.co) in September and issued $258.8 million of 2.00% convertible notes, its 10-Q filed Thursday shows. Over the same stretch its board has kept a $500.0 million buyback authorization on the books, and no shares have been repurchased this year.

## Stock, notes and an idle buyback

The share sale brought in gross proceeds of about $316.25 million, and the notes added about $258.8 million. After fees, net proceeds were about $296.9 million and $250.6 million. The offerings included full exercise of the underwriters' options.

In July the board [ended a $250.0 million repurchase plan and authorized up to $500.0 million](https://www.sec.gov/Archives/edgar/data/0001607678/000119312526324219/vktx-20260630.htm?ref=bullished.co) over up to three years. The 10-Q says nothing was repurchased under either plan in the nine months ended September 30, 2026.

Viking also sold 1,476,600 shares through its at-the-market program, which lets it sell stock at market prices. Up to $449.8 million remains available under it.

## What the notes could mean for share count

The notes mature October 15, 2032\. Conversion at about $50.75 per share could add roughly 5,098,514 shares, though Viking may pay in cash instead.

Shares outstanding stood at 127,521,229 at September 30, up from 114,793,067 at the end of 2025.

## R&D nearly doubles as cash swells

Viking has no revenue. Research and development spending reached $166.8 million in the third quarter, against $89.953 million a year earlier, and the net loss was $183.2 million, or $1.55 per share. For the nine months, R&D was $432.7 million, mostly on the two Phase 3 VANQUISH trials of its lead obesity drug, VK2735.

Liquidity, including restricted cash and short-term investments, reached $960.0 million at September 30, versus $501.9 million three months earlier. Management says that funds operations through at least December 31, 2027, compared with September 30, 2027 in the prior filing. The company also says it will need to raise more capital to finish its ongoing and planned trials.

In October it started the SUNRISE Phase 3 program for an oral version of VK2735.

Ligand wants Viking's contract cross-claims dismissed; Viking's response is due February 11, with a court date February 26, 2027.

### Sources

- [10-Q Filing — Viking Therapeutics (VKTX)](https://www.sec.gov/Archives/edgar/data/0001607678/000119312526436432/vktx-20260930.htm?ref=bullished.co) — SEC EDGAR
- [10-Q Filing — Viking Therapeutics (VKTX), Q2 FY2026 filed 2026-07-29 (comparison basis)](https://www.sec.gov/Archives/edgar/data/0001607678/000119312526324219/vktx-20260630.htm?ref=bullished.co) — SEC EDGAR
- [Earnings release (8-K Item 2.02, vktx-ex99\_1.htm) — Viking Therapeutics, filed 2026-10-28](https://www.sec.gov/Archives/edgar/data/0001607678/000119312526436145/vktx-ex99%5F1.htm?ref=bullished.co) — SEC EDGAR
- [Viking outlines \~$100M average quarterly cash usage as Phase III SUNRISE and VANQUISH advance (NASDAQ:VKTX) | Seeking Alpha](https://seekingalpha.com/news/4659793-viking-outlines-100m-average-quarterly-cash-usage-as-phase-iii-sunrise-and-vanquish-advance?ref=bullished.co) — seekingalpha.com
- [Viking Therapeutics (VKTX) Posted Wider Losses, Is The Stock Overvalued?](https://finance.yahoo.com/markets/stocks/articles/viking-therapeutics-vktx-posted-wider-081818204.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update](https://finance.yahoo.com/healthcare/articles/viking-therapeutics-reports-third-quarter-200500003.html?ref=bullished.co) — Yahoo Finance
- [Viking Therapeutics quarterly net loss doubles as R&D expenses surge | Seeking Alpha](https://seekingalpha.com/news/4659723-viking-therapeutics-quarterly-net-loss-doubles-research-development-expenses-surge?ref=bullished.co) — seekingalpha.com
- [Viking Therapeutics GAAP EPS of -$1.55 misses by $0.50 (VKTX:NASDAQ) | Seeking Alpha](https://seekingalpha.com/news/4659567-viking-therapeutics-gaap-eps-of-1%5F55-misses-by-0%5F50?ref=bullished.co) — seekingalpha.com

### More on Viking Therapeutics

- [Viking CEO Eyes Outside Obesity Deals After $575 Million Raise, Favors Own Pipeline](https://www.bullished.co/viking-ceo-eyes-outside-obesity-deals-after-575-million-raise-favors-own-pipeline-fddbf108/)
- [Viking Wants A Maintenance Dosing Label For VK2735, But Says The Filing Plan Is 'TBD'](https://www.bullished.co/viking-wants-a-maintenance-dosing-label-for-vk2735-but-says-the-filing-plan-is-tbd-6d71eaec/)
- [Viking Therapeutics Loss Doubles To $183 Million As Obesity Drug Trials Multiply](https://www.bullished.co/viking-therapeutics-loss-doubles-to-183-million-as-obesity-drug-trials-multiply-4ecb7fce/)

[All Viking Therapeutics (VKTX) coverage →](https://www.bullished.co/tag/vktx/)